203 studies found for:    "systemic scleroderma"
Show Display Options
Rank Status Study
21 Completed Scleroderma Lung Study
Conditions: Lung Diseases;   Pulmonary Fibrosis;   Systemic Scleroderma;   Scleroderma, Systemic
Interventions: Drug: cyclophosphamide;   Drug: azathioprine
22 Terminated
Has Results
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Conditions: Systemic Scleroderma;   Pulmonary Hypertension
Interventions: Drug: Bosentan;   Drug: Placebo
23 Not yet recruiting Zibotentan Better Renal Scleroderma Outcome Study
Conditions: Scleroderma;   Scleroderma Renal Crisis;   Chronic Kidney Disease
Intervention: Drug: Zibotentan
24 Completed
Has Results
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
Condition: SYSTEMIC SCLERODERMA
Interventions: Drug: standard of care;   Procedure: stem cell transplantation
25 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.
26 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
27 Active, not recruiting A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Conditions: Pulmonary Arterial Hypertension;   Systemic Sclerosis;   Scleroderma Spectrum of Diseases;   Connective Tissue Disease;   Pulmonary Hypertension
Interventions: Drug: Tadalafil monotherapy;   Drug: Ambrisentan monotherapy;   Drug: tadalafil and ambrisentan
28 Completed Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
Conditions: Systemic Scleroderma;   Skin Fibrosis;   Hand Functionality
Intervention: Drug: Bosentan (Tracleer)
29 Active, not recruiting Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Conditions: Scleroderma;   Interstitial Lung Disease
Interventions: Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Placebo
30 Completed Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Condition: Systemic Scleroderma
Interventions: Drug: Sildenafil;   Drug: placebo
31 Completed
Has Results
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Condition: Scleroderma, Systemic
Intervention: Drug: Mycophenolate mofetil
32 Completed Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Procedure: standardized reeducation and readaptation program
33 Withdrawn Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
34 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
35 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: mycophenolate mofetil;   Drug: plerixafor
36 Recruiting Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
37 Unknown  Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls
Condition: Scleroderma
Intervention:
38 Recruiting Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma
Conditions: Scleroderma;   Systemic Sclerosis
Intervention: Drug: Divalproex sodium
39 Terminated Immunoadsorption in Patients With Severe Systemic Sclerosis
Condition: Systemic Scleroderma
Intervention: Device: TheraSorb Ig
40 Terminated Treatment of Early Systemic Sclerosis by Bosentan
Condition: Systemic Sclerosis (Scleroderma)
Intervention: Drug: bosentan

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years